A Quality Improvement Approach to Optimizing Medication Use in the Neonatal Intensive Care Unit

Clinics in Perinatology

Volumn 39, Issue 1, 2012, Pages 1-10

  Ellsbury, Dan L ^a   Ursprung, Robert ^a  

^a PEDIATRIX MEDICAL GROUP   (United States)

Author keywords

Iatrogenesis; Medication; Neonatology; Quality improvement

Indexed keywords

ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; BENZYL ALCOHOL; CHLORAMPHENICOL; CORTICOSTEROID; DEXAMETHASONE; ERYTHROMYCIN; ERYTHROPOIETIN; HEXACHLOROPHENE; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOMETACIN; MACROGOL; MAGNESIUM SULFATE; METOCLOPRAMIDE; OXYGEN; SPIRONOLACTONE; SULFAFURAZOLE; SURFACTANT; VITAMIN K GROUP;

ADVERSE DRUG REACTION; BRAIN DAMAGE; BRAIN HEMORRHAGE; CEREBRAL PALSY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG MISUSE; DRUG MONITORING; DRUG SAFETY; DRUG USE; ESOPHAGITIS; GASPING SYNDROME; GASTRITIS; GRAY BABY SYNDROME; HEALTH CARE QUALITY; HEALTH EDUCATION; HUMAN; IATROGENIC DISEASE; INTENSIVE CARE UNIT; INTESTINE PERFORATION; KERNICTERUS; LUNG DYSPLASIA; MAGNESIUM TOXICITY; MULTIORGAN DAMAGE; NEWBORN; NEWBORN INTENSIVE CARE; NEWBORN MORBIDITY; NEWBORN MORTALITY; PHARMACEUTICAL CARE; POSTNATAL CARE; PRACTICE GUIDELINE; PREMATURITY; PRENATAL CARE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PROPHYLAXIS; PYLORUS STENOSIS; QUALITY CONTROL; RETROLENTAL FIBROPLASIA; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEIZURE; TREATMENT DURATION;

BIRTH WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; GESTATIONAL AGE; HUMANS; IATROGENIC DISEASE; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INTENSIVE CARE UNITS, NEONATAL; MEDICATION ERRORS; NEONATOLOGY; PATIENT SAFETY; PHARMACEUTICAL PREPARATIONS; QUALITY IMPROVEMENT;

EID: 84857088009     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2011.12.001     Document Type: Review

References (62)

1. Allegaert K. Mechanism based medicine in infancy: complex interplay between developmental pharmacology and pharmacogenetics. Int J Clin Pharm 2011, 33(3):473-474.
2. Allegaert K., Verbesselt R., Naulaers G., et al. Developmental pharmacology: neonates are not just small adults. Acta Clin Belg 2008, 63(1):16-24.
3. Leviton L.C., Goldenberg R.L., Baker C.S., et al. Methods to encourage the use of antenatal corticosteroid therapy for fetal maturation: a randomized controlled trial. JAMA 1999, 281(1):46-52.
4. Ellsbury D.L. Crossing the quality chasm in neonatal-perinatal medicine. Clin Perinatol 2010, 37(1):1-10.
5. Robertson A.F. Reflections on errors in neonatology: I. The "Hands-Off" years, 1920 to 1950. J Perinatol 2003, 23(1):48-55.
6. Robertson A.F. Reflections on errors in neonatology: II. The "Heroic" years, 1950 to 1970. J Perinatol 2003, 23(2):154-161.
7. Robertson A.F. Reflections on errors in neonatology III. The "experienced" years, 1970 to 2000. J Perinatol 2003, 23(3):240-249.
8. Ambalavanan N., Walsh M., Bobashev G., et al. Intercenter differences in bronchopulmonary dysplasia or death among very low birth weight infants. Pediatrics 2011, 127(1):e106-e116.
9. Horbar J.D., Badger G.J., Lewit E.M., et al. Hospital and patient characteristics associated with variation in 28-day mortality rates for very low birth weight infants. Vermont Oxford Network. Pediatrics 1997, 99(2):149-156.
10. Finer N.N., Carlo W.A., Walsh M.C., et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010, 362(21):1970-1979.
11. Morley C.J., Davis P.G., Doyle L.W., et al. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 2008, 358(7):700-708.
12. Dunn M.S., Kaempf J., de Klerk A., et al. Randomized trial comparing 3 approaches to the initial respiratory management of preterm neonates. Pediatrics 2011, 128(5):e1069-e1076.
13. Fowlie P.W., Davis P.G., McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2010, 7. CD000174.
14. Ment L.R., Oh W., Ehrenkranz R.A., et al. Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics 1994, 93(4):543-550.
15. Schmidt B., Davis P., Moddemann D., et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001, 344(26):1966-1972.
16. Aher S., Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006, 3. CD004868.
17. Aher S.M., Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006, 3. CD004865.
18. Ohlsson A., Aher S.M. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006, 3. CD004863.
19. Suk K.K., Dunbar J.A., Liu A., et al. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model. J AAPOS 2008, 12(3):233-238.
20. Almirante B., Rodriguez D. Antifungal agents in neonates: issues and recommendations. Paediatr Drugs 2007, 9(5):311-321.
21. Avent M.L., Kinney J.S., Istre G.R., et al. Gentamicin and tobramycin in neonates: comparison of a new extended dosing interval regimen with a traditional multiple daily dosing regimen. Am J Perinatol 2002, 19(8):413-420.
22. Baley J.E., Meyers C., Kliegman R.M., et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990, 116(5):791-797.
23. Bartelink I.H., Rademaker C.M., Schobben A.F., et al. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006, 45(11):1077-1097.
24. DiCenzo R., Forrest A., Slish J.C., et al. A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates. Pharmacotherapy 2003, 23(5):585-591.
25. Fullas F., Padomek M.T., Thieman C.J., et al. Comparative evaluation of six extended-interval gentamicin dosing regimens in premature and full-term neonates. Am J Health Syst Pharm 2011, 68(1):52-56.
26. Watterberg K.L., Papile L.A., Adamkin D.H. American Academy of Pediatrics. Committee on Fetus and Newborn. Policy statement-postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010, 126(4):800-808.
27. Doyle L.W., Halliday H.L., Ehrenkranz R.A., et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 2005, 115(3):655-661.
28. Halliday H.L., Ehrenkranz R.A., Doyle L.W. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009, 1. CD001145.
29. Halliday H.L., Ehrenkranz R.A., Doyle L.W. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009, 1. CD001146.
30. Clark R.H., Bloom B.T., Spitzer A.R., et al. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006, 117(6):1979-1987.
31. Walsh M.C., Yao Q., Horbar J.D., et al. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 2006, 118(5):e1328-e1335.
32. Ursprung R., Gray J. Random safety auditing, root cause analysis, failure mode and effects analysis. Clin Perinatol 2010, 37(1):141-165.
33. Hibbs A.M., Lorch S.A. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics 2006, 118(2):746-752.
34. Kimball A.L., Carlton D.P. Gastroesophageal reflux medications in the treatment of apnea in premature infants. J Pediatr 2001, 138(3):355-360.
35. Bancalari E. Apnea is not prolonged by acid gastroesophageal reflux in preterm infants. Pediatrics 2005, 116(5):1217-1218.
36. Clark R.H., Spitzer A.R. Patience is a virtue in the management of gastroesophageal reflux. J Pediatr 2009, 155(4):464-465.
37. Di Fiore J.M., Arko M., Whitehouse M., et al. Apnea is not prolonged by acid gastroesophageal reflux in preterm infants. Pediatrics 2005, 116(5):1059-1063.
38. Wheatley E., Kennedy K.A. Cross-over trial of treatment for bradycardia attributed to gastroesophageal reflux in preterm infants. J Pediatr 2009, 155(4):516-521.
39. Graham P.L., Begg M.D., Larson E., et al. Risk factors for late onset gram-negative sepsis in low birth weight infants hospitalized in the neonatal intensive care unit. Pediatr Infect Dis J 2006, 25(2):113-117.
40. Guillet R., Stoll B.J., Cotten C.M., et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006, 117(2):e137-e142.
41. Saiman L., Ludington E., Pfaller M., et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Dis J 2000, 19(4):319-324.
42. Ellsbury D.L., Ursprung R. A primer on quality improvement methodology in neonatology. Clin Perinatol 2010, 37(1):87-99.
43. Batalden P.B., Nelson E.C., Edwards W.H., et al. Microsystems in health care: part 9. Developing small clinical units to attain peak performance. Jt Comm J Qual Saf 2003, 29(11):575-585.
44. Cole C.H. Postnatal glucocorticosteroid therapy for treatment and prevention of neonatal chronic lung disease. Expert Opin Investig Drugs 2000, 9(1):53-67.
45. Cotten C.M., McDonald S., Stoll B., et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 2006, 118(2):717-722.
46. Clark R.H., Bloom B.T., Spitzer A.R., et al. Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics 2006, 117(1):67-74.
47. Benjamin D.K., Stoll B.J., Fanaroff A.A., et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006, 117(1):84-92.
48. Benjamin D.K., Stoll B.J., Gantz M.G., et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics 2010, 126(4):e865-e873.
49. Cantey J.B., Sanchez P.J. Prolonged antibiotic therapy for "culture-negative" sepsis in preterm infants: it's time to stop!. J Pediatr 2011, 159(5):707-708.
50. Cotten C.M., Taylor S., Stoll B., et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics 2009, 123(1):58-66.
51. Mejia N.I., Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord 2005, 20(1):86-89.
52. Putnam P.E., Orenstein S.R., Wessel H.B., et al. Tardive dyskinesia associated with use of metoclopramide in a child. J Pediatr 1992, 121(6):983-985.
53. Rao A.S., Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010, 31(1):11-19.
54. Hoffman D.J., Gerdes J.S., Abbasi S. Pulmonary function and electrolyte balance following spironolactone treatment in preterm infants with chronic lung disease: a double-blind, placebo-controlled, randomized trial. J Perinatol 2000, 20(1):41-45.
55. Swiglo B.A., Cosma M., Flynn D.N., et al. Clinical review: antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008, 93(4):1153-1160.
56. Vachharajani A.J., Shah J.K., Paes B.A. Ovarian cyst in a premature infant treated with spironolactone. Am J Perinatol 2001, 18(6):353-356.
57. Chen M.L., Guo L., Smith L.E., et al. High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics 2010, 125(6):e1483-e1492.
58. Ellsbury D.L., Ursprung R. Comprehensive oxygen management for the prevention of retinopathy of prematurity: the pediatrix experience. Clin Perinatol 2010, 37(1):203-215.
59. Johnson K., Scott S.D., Fraser K.D. Oxygen use for preterm infants: factors that may influence clinical decisions surrounding oxygen titration. Adv Neonatal Care 2011, 11(1):8-14. [quiz: 15-6].
60. Carlo W.A., Finer N.N., Walsh M.C., et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 2010, 362(21):1959-1969.
61. Saugstad O.D. Oxygen and oxidative stress in bronchopulmonary dysplasia. J Perinat Med 2010, 38(6):571-577.
62. Saugstad O.D., Aune D. In search of the optimal oxygen saturation for extremely low birth weight infants: a systematic review and meta-analysis. Neonatology 2010, 100(1):1-8.